Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
- Registration Number
- NCT05226494
- Lead Sponsor
- NanoPharmaceuticals LLC
- Brief Summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
- Histologically proven intracranial glioblastoma, with first or second recurrence
- On stable or decreasing dose of steroids, if taken prior to screening
- Baseline MRI (with and without contrast) completed with 5 days of starting fb-PMT
- Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
- Confirmation of true progressive disease for patients previously treated with interstitial brachytherapy or stereotactic radio surgery
- Life expectancy of more than three months
- Karnofsky Performance Status of ≥ 70
- Hypertension must be well controlled (≤ 95th percentile) on stable doses of medication
- Adequate bone marrow and organ function, confirmed by laboratory testing at screening
- Patient or caregiver must be able to store drug under refrigerated conditions, prepare and administer daily subcutaneous injections on a set schedule, and record information in a daily treatment diary
- Women of childbearing potential must agree to ongoing pregnancy testing and to use medically acceptable contraception for the duration of the study and for 2 months after their last dose of study drug
- Males must agree to use medically acceptable contraception and refrain from donating sperm for the duration of the study and for 2 months after their last dose of study drug
Exclusion Criteria
- Significant medical illness that is uncontrolled, may obscure toxicity, may dangerously alter drug metabolism, or may compromise ability for study participation
- History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for at least 3 months prior to first dose of study drug
- Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
- Prior therapy with fb-PMT or related drugs
- Currently pregnant or breastfeeding
- Active infection or serious intercurrent medical illness
- Surgery of any type within the preceding 28 days that has not fully healed
- A serious or non-healing wound, ulcer, or bone fracture
- A known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment
- A known thrombophilic condition (i.e., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome). Testing is not required in patients without thrombophilic history.
- Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to study enrollment
- Clinically significant cardiovascular event such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.
- New York Heart Association classification of heart disease greater than Class 2
- QTc interval > 450 msec in males or > 470 msec in females at screening
- Use of concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes
- Use of any concomitant OATP1B1, OATP1B3, or BSEP inhibitors within 14 days or five half-lives (whichever is longer) before starting study drug treatment
- Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment
- A significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study enrollment
- History of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months
- History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Treatment (fb-PMT) fb-PMT Daily subcutaneous injection of fb-PMT in four escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.
- Primary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] 15 months Determined by the number of Treatment-Emergent Adverse Events, including Dose-Limiting Toxicities per patient.
Incidence of Dose Limiting Toxicities [Safety and Tolerability] 28 Days Number of participants with a dose-limiting toxicity during the first cycle (28 days) of treatment at their highest dose level administered.
- Secondary Outcome Measures
Name Time Method Establishment of Recommended Phase 2 Dose 28 Days Maximum Tolerated Dose, as determined by Dose-Limiting Toxicities.
Trial Locations
- Locations (1)
Smilow Cancer Hospital
🇺🇸New Haven, Connecticut, United States